In yesterday’s Wall Street session, Seres Therapeutics Inc (NASDAQ:MCRB) shares traded at $0.69, down -2.82% from the previous session.
MCRB stock price is now -28.20% away from the 50-day moving average and -67.51% away from the 200-day moving average. The market capitalization of the company currently stands at $104.11M.
On April 21, 2023, JP Morgan recently initiated its ‘Neutral’ rating on the stock quoting a target price of $7, while ‘Goldman’ rates the stock as ‘Sell’
In other news, Shaff Eric D., CEO and President sold 11,549 shares of the company’s stock on Feb 16 ’24. The stock was sold for $12,473 at an average price of $1.08. Upon completion of the transaction, the CEO and President now directly owns 135,321 shares in the company, valued at $93371.49. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 16 ’24, Ege David S. sold 5,010 shares of the business’s stock. A total of $5,411 was realized by selling the stock at an average price of $1.08. This leaves the insider owning 73,856 shares of the company worth $50960.64. A total of 24.42% of the company’s stock is owned by insiders.
During the past 12 months, Seres Therapeutics Inc has had a low of $0.69 and a high of $6.87. The fifty day moving average price for MCRB is $0.9602 and a two-hundred day moving average price translates $2.1216 for the stock.
The latest earnings results from Seres Therapeutics Inc (NASDAQ: MCRB) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.32, beating analysts’ expectations of -$0.5 by 0.18. This compares to -$0.51 EPS in the same period last year. The net profit margin was -90.02% and return on equity was -538.57% for MCRB. The company reported revenue of $64000.0 for the quarter, compared to $0.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -93.44 percent. For the current quarter, analysts expect MCRB to generate $250k in revenue.
